NCT04017546View on ClinicalTrials.gov

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 2, 2019

Primary Completion Date

November 15, 2022

Study Completion Date

April 5, 2023

Conditions
AMLMDS
Interventions
DRUG

CYC065

intravenous infusion

DRUG

Venetoclax

oral capsule

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT04017546 - CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS | Biotech Hunter | Biotech Hunter